You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Details for Patent: RE46965

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE46965 protect, and when does it expire?

Patent RE46965 protects HALAVEN and is included in one NDA.

This patent has thirty-six patent family members in twelve countries.

Summary for Patent: RE46965
Title:Intermediates for the preparation of analogs of Halichondrin B
Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4). ##STR00001##
Inventor(s): Austad; Brian (Tewksbury, MA), Chase; Charles E. (Londonderry, NH), Fang; Francis G. (Andover, MA), Calkins; Trevor (Stoughton, WI), Lewis; Bryan M. (North Brunswick, NJ)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:13/924,892
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent RE46965

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46965

PCT Information
PCT FiledJune 03, 2005PCT Application Number:PCT/US2005/019669
PCT Publication Date:December 15, 2005PCT Publication Number: WO2005/118565

International Family Members for US Patent RE46965

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005250487   Start Trial
Canada 2567984   Start Trial
Canada 2822994   Start Trial
Canada 2935786   Start Trial
Canada 3028453   Start Trial
China 101899026   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.